| Title |
A case of interstitial lung disease with alveolar hemorrhage induced by pembrolizumab
|
|---|---|
| Published in |
OncoTargets and therapy, September 2018
|
| DOI | 10.2147/ott.s169321 |
| Pubmed ID | |
| Authors |
Teppei Sugano, Masahiro Seike, Rintaro Noro, Syota Kaburaki, Takehiro Tozuka, Akihiko Takahashi, Natsuki Takano, Toru Tanaka, Takeru Kashiwada, Susumu Takeuchi, Yuji Minegishi, Yoshinobu Saito, Kaoru Kubota, Yasuhiro Terasaki, Akihiko Gemma |
| Abstract |
We herein describe the case of a 67-year-old woman with advanced lung adenocarcinoma who developed interstitial lung disease (ILD) with alveolar hemorrhage induced by pembrolizumab. She received four courses of pembrolizumab therapy and achieved a partial response. She had no respiratory symptoms; however, chest radiography and computed tomography (CT) revealed ground-glass opacities (GGOs) and crazy-paving pattern. Based on findings of bloody bronchoalveolar lavage fluid and transbronchial lung biopsy samples, pembrolizumab-induced ILD with alveolar hemorrhage was diagnosed. Corticosteroid therapy rapidly improved alveolar hemorrhage and regressed GGOs on CT scan. This is the first report on ILD with alveolar hemorrhage induced by pembrolizumab. |
Mendeley readers
The data shown below were compiled from readership statistics for 15 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 15 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 3 | 20% |
| Other | 3 | 20% |
| Student > Postgraduate | 2 | 13% |
| Researcher | 2 | 13% |
| Unknown | 5 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 7 | 47% |
| Biochemistry, Genetics and Molecular Biology | 1 | 7% |
| Unknown | 7 | 47% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 September 2018.
All research outputs
#22,767,715
of 25,385,509 outputs
Outputs from OncoTargets and therapy
#2,080
of 3,016 outputs
Outputs of similar age
#302,660
of 345,739 outputs
Outputs of similar age from OncoTargets and therapy
#103
of 147 outputs
Altmetric has tracked 25,385,509 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,016 research outputs from this source. They receive a mean Attention Score of 2.9. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 345,739 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 147 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.